Latest Relaxin Stories
As it turns out, having one human person growing inside another human person can have some dramatic effects.
After a four-week course of the vasodilator hormone relaxin, kidney function and blood flow immediately improved in lab rats genetically altered to model polycystic kidney disease (PKD), a life-threatening genetic disorder.
SAN MATEO' Calif.' Oct. 1 /PRNewswire/ -- Corthera Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to relaxin, the company's investigational drug for the treatment of acute heart failure (AHF).
Data from Phase II/III Study Presented at Heart Failure Congress 2009 Demonstrate Promising Safety and Efficacy Results for Relaxin SAN MATEOâ€š Calif.â€š June 1 /PRNewswire/ -- Corthera Inc.
SAN MATEOâ€š Calif.â€š May 28 /PRNewswire/ -- Results and additional analyses from the Phase II portion of a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented at the Heart Failure Congress, the annual meeting of the Heart Failure Association of the European Society of Cardiology in Nice, France.
Data Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session; Results Published On-Line in The Lancet SAN MATEOâ€š Calif.â€š March 29 /PRNewswire/ -- Corthera Inc.
SAN MATEOâ€š Calif.â€š March 23 /PRNewswire/ -- Results from the Phase II portion of a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented at 10:30 a.m.
SAN MATEO, Calif., Nov.
- A hairdresser.